Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro Diagnostics

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1587947

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1587947

Antimicrobial Susceptibility Testing Market by Product (Manual, Automated, Molecular), Method, Type, Application Global Forecasts to 2029

PUBLISHED:
PAGES: 283 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The global antimicrobial susceptibility testingmarket is projected to reach USD 5.68 billion by 2029 from USD 4.45 billion in 2024, growing at a CAGR of 5.0% % during the forecast period. Key advantages of the AST market include the fact that it is very crucial in improving patient care through proper identification and timely selection of effective antimicrobial therapy. AST therefore has an added advantage in combating the rise of the antimicrobial resistance problem in providing correct susceptibility profiles that assist appropriate antibiotic usage.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD Million)
SegmentsBy Product, Type, Method, Application, End User and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa

"Consumables to register largest market share in 2022-2029."

The largest share in antimicrobial susceptibility testing (AST) is held by the consumables segment. A significant and ever-increasing amount of critical material is consumed. It comprises culture media, reagents, antibiotic discs, and other materials and can be considered basically necessary for AST procedures. The market share of the consumable is thus added to owing to the growing incidence of infectious diseases and the emergence of antibiotic-resistant pathogens and increasing demand for AST services.

Second, the production of more sophisticated AST technologies will need more technical consumables. Obviously, molecular-based AST methods will require specific nucleic acid extraction kits, PCR reagents, and detection probes. Persistent demand for accurate and effective AST testing creates a sustainable demand for consumables, which further solidifies them as the core of the overall AST market.

"Hospitals & diagnostic centers segment held the largest share of antimicrobial susceptibility testingmarket in 2023, by End-user."

Based on the end-user, the antimicrobial susceptibility testing market is segmented into hospitals & diagnostic laboratories, pharmaceutical and biotechnology companies, research & academic Institutes and clinical research organizations. In the year 2023, the global antimicrobial susceptibility testing market was dominated by hospitals and diagnostic centers. Growth within the number of hospitals and diagnostic centers in the AST market is also derived from increases in the timely and accurate diagnostics needs for managing infectious diseases and fighting against antimicrobial resistance.

.

"Asia Pacific to register highest growth rate in the market during the forecast period."

The Asia Pacific region, and China in particular, is witnessing a very rapid growth in the AST market due to various reasons. The increasing population in this region, allied with increasing incomes and access to better health care, has resulted in more stringent demands for diagnostics services. It is not overstressed in the sense that the ever-growing occurrence of infectious diseases and antimicrobial-resistant pathogens demands utmost importance in attaching real value to accurate AST as the primary basis for guiding proper treatment.

Advances in AST technology, particularly through the development of molecular rapid diagnostics and automated systems, is driving the market.. These speed up the process of AST, give results quicker in turn-around time, have increased efficiency with precise results, which put AST within the reach of healthcare providers. Additionally, the investments done by governments in upgrading the health care infrastructure along with such initiatives have paved a favorable path toward the growth of the market in the country, particularly in China.

A number of drivers were responsible for the upswing, including:

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1-30%, Tier 2-42%, and Tier 3- 28%
  • By Designation: C-level-- 10%, Director-level-14%, and Others-76%
  • By Region: North America-40%, Europe-30%, Asia Pacific-20%, Latin America- 5%, Middle east and africa- 5%

Prominent players in this market are BioMerieux (France), Becton, Dickinson and company (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Bio-Rad laboratories (US), Bruker (US), Roche diagnostics (Switzerland, Accelerate diagnostics (US), Himedia laboratories (India), Liofilchem s.r.l.(Italy), Alifax s.r.l.(Italy), Creative Diagnostics (US), among others.

Research Coverage

The market is segmented into product, type, method, application, end user, and region. In the report, factors affecting the antimicrobial susceptibility testing market- drivers, restraints, opportunities, and challenges-are described. Opportunities and challenges for stakeholders and the details of leading players' competitive landscape are also highlighted. The report further segments the micro-markets into growth trends, prospects, and contribution to the antimicrobial susceptibility testing market. It forecasts revenue growth from different market segments, focusing on five major geographical regions.

Key Benefits of Buying the Report:

The report is designed to aid new entrants by providing them with detailed data on the antimicrobial susceptibility testing market, thereby allowing them to understand investment opportunities. It provides comprehensive insight into key players as well as smaller ones, thus favoring strong risk assessment and informed investment decisions. Due to precise segmentation-such as by end-users and regions-the report offers focused insights in specific segments of the market. It further outlines the critical trends, challenges, growth drivers, and opportunities that complete the strategic decision-making process with well-rounded analysis.

The report provides the insights on the following pointers:

Analysis of the key drivers, restraints, opportunities, and challenges influencing the rise of the antimicrobial susceptibility testing market. The key drivers of antimicrobial susceptibility testing are an upsurge in infectious diseases and, correspondingly, higher numbers of antibiotic resistance around the world. Growing demand for timely and accurate diagnostic tools that guide effective treatment strategies fuels demand for AST. Technologically, the development of rapid and automated testing systems supports market growth by increasing efficiency and accuracy in tests.

Product Development/Innovation: Insights into emerging technologies, current R&D activities, and recent launches of products and services in the antimicrobial susceptibility testing market.

Market Development: The report further provides in detail the profitable markets by segmenting the antimicrobial susceptibility testing market into various regions

Market Diversification: Detailed insight into new product launches, unexplored markets, recent developments, and investments made in the antimicrobial susceptibility testing market.

Competitive Assessment: Detailed assessment of market share, service offerings leading strategies of key players such as BioMerieux (France), Becton, Dickinson and company (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Bio-Rad laboratories (US), among others.

Show more
Product Code: MD 5931

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 INCLUSIONS AND EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH DESIGN
    • 2.2.1 SECONDARY RESEARCH
    • 2.2.2 PRIMARY RESEARCH
      • 2.2.2.1 Primary sources
      • 2.2.2.2 Key industry insights
      • 2.2.2.3 Breakdown of primaries
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
      • 2.3.1.1 Approach 1: Company revenue estimation approach
      • 2.3.1.2 Approach 2: Customer-based market estimation
      • 2.3.1.3 Approach 3: Top-down approach
      • 2.3.1.4 Approach 4: Primary interviews
      • 2.3.1.5 CAGR projections
  • 2.4 DATA TRIANGULATION & MARKET BREAKDOWN
  • 2.5 MARKET SHARE ASSESSMENT
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 ASSUMPTIONS/MARKET FORECASTING METHODOLOGY
  • 2.8 LIMITATIONS AND RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET OVERVIEW
  • 4.2 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
  • 4.3 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION AND END USER, 2023 (USD MILLION)
  • 4.4 GEOGRAPHIC GROWTH OPPORTUNITIES IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising antimicrobial resistance
      • 5.2.1.2 Advancements in diagnostic technologies
      • 5.2.1.3 Expansion of clinical research applications
      • 5.2.1.4 Rise in government initiatives
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of automated instruments
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emergence of rapid testing solutions
      • 5.2.3.2 Integration with digital health technologies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Intricate regulatory landscape
  • 5.3 INDUSTRY TRENDS
    • 5.3.1 ISOTHERMAL MICROCALORIMETRY
    • 5.3.2 FLUORESCENCE-ACTIVATED CELL SORTING
    • 5.3.3 SMARTPHONE-BASED OPTICAL SPECTROSCOPY
    • 5.3.4 MICROFLUIDICS AND MICRODROPLETS
  • 5.4 ECOSYSTEM ANALYSIS
  • 5.5 SUPPLY CHAIN ANALYSIS
    • 5.5.1 PROMINENT COMPANIES
    • 5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES
    • 5.5.3 END USERS
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 PORTER'S FIVE FORCES ANALYSIS
    • 5.7.1 THREAT OF NEW ENTRANTS
    • 5.7.2 BARGAINING POWER OF SUPPLIERS
    • 5.7.3 BARGAINING POWER OF BUYERS
    • 5.7.4 THREAT OF SUBSTITUTES
    • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.8.2 BUYING CRITERIA
  • 5.9 PATENT ANALYSIS
  • 5.10 TRADE ANALYSIS
    • 5.10.1 IMPORT DATA
    • 5.10.2 EXPORT DATA
  • 5.11 KEY CONFERENCES AND EVENTS, 2024-2025
  • 5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.13 TECHNOLOGY ANALYSIS
    • 5.13.1 KEY TECHNOLOGIES
      • 5.13.1.1 PCR
      • 5.13.1.2 Microfluidics and lab-on-a-chip
      • 5.13.1.3 Synthetic antimicrobial peptides
    • 5.13.2 COMPLIMENTARY TECHNOLOGIES
      • 5.13.2.1 MALDI-TOF
    • 5.13.3 ADJACENT TECHNOLOGIES
      • 5.13.3.1 Nanotechnology
      • 5.13.3.2 Nanomotion technology
      • 5.13.3.3 Biochip technology
  • 5.14 REGULATORY LANDSCAPE
    • 5.14.1 NORTH AMERICA
      • 5.14.1.1 US
      • 5.14.1.2 Canada
    • 5.14.2 EUROPE
    • 5.14.3 ASIA PACIFIC
      • 5.14.3.1 Japan
      • 5.14.3.2 China
      • 5.14.3.3 India
    • 5.14.4 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.15 INVESTMENT AND FUNDING SCENARIO
  • 5.16 PRICING ANALYSIS
    • 5.16.1 AVERAGE SELLING PRICE, BY REGION
    • 5.16.2 AVERAGE SELLING PRICE, BY KEY PLAYER
  • 5.17 REIMBURSEMENT SCENARIO
  • 5.18 UNMET NEEDS AND KEY PAIN POINTS
  • 5.19 IMPACT OF AI/GEN AI ON ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET

6 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 CONSUMABLES
    • 6.2.1 CULTURE & GROWTH MEDIA
      • 6.2.1.1 High utilization of disk diffusion and broth dilution methods to drive market
    • 6.2.2 SUSCEPTIBILITY TESTING DISKS
      • 6.2.2.1 Low costs, ease of use to support adoption
    • 6.2.3 MIC STRIPS
      • 6.2.3.1 Accuracy, simplicity, and thorough results to drive usage
    • 6.2.4 SUSCEPTIBILITY TESTING PLATES
      • 6.2.4.1 Availability of specialized plates to drive market
  • 6.3 LAB INSTRUMENTS
    • 6.3.1 AUTOMATED LABORATORY INSTRUMENTS
      • 6.3.1.1 Ongoing trend of laboratory automation to fuel segment growth
    • 6.3.2 MOLECULAR DIAGNOSTICS SYSTEMS
      • 6.3.2.1 Technological advancements in molecular diagnostics to propel market
  • 6.4 LAB DISPOSABLES
    • 6.4.1 INCREASING NUMBER OF SUSCEPTIBILITY TESTS PERFORMED IN HOSPITALS TO DRIVE DEMAND

7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE

  • 7.1 INTRODUCTION
  • 7.2 ANTIBACTERIAL SUSCEPTIBILITY TESTING
    • 7.2.1 EMERGENCE OF MULTIDRUG-RESISTANCE TO INCREASE ADOPTION OF ANTIBACTERIAL SUSCEPTIBILITY TESTING PRODUCTS
  • 7.3 ANTIFUNGAL SUSCEPTIBILITY TESTING
    • 7.3.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO PROPEL DEMAND FOR TESTING
  • 7.4 ANTIPARASITIC SUSCEPTIBILITY TESTING
    • 7.4.1 RISING AWARENESS TO SUPPORT MARKET GROWTH
  • 7.5 ANTIVIRAL SUSCEPTIBILITY TESTING
    • 7.5.1 ADVANCEMENTS IN ANTIVIRAL SUSCEPTIBILITY TESTING TO ENHANCE PATIENT OUTCOMES

8 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD

  • 8.1 INTRODUCTION
  • 8.2 QUALITATIVE METHODS
    • 8.2.1 AUTOMATED AST
      • 8.2.1.1 Advancements and resistance patterns to drive use of automated instruments
    • 8.2.2 DISK DIFFUSION
      • 8.2.2.1 Simplicity, accuracy, and flexibility to support adoption
    • 8.2.3 AGAR DILUTION
      • 8.2.3.1 Time-consuming and labor-intensive nature to affect adoption
    • 8.2.4 GENOTYPIC METHOD
      • 8.2.4.1 Gold standard status to support greater adoption
  • 8.3 QUANTITATIVE METHODS
    • 8.3.1 ETEST METHOD
      • 8.3.1.1 Etest to hold larger share of quantitative methods market
    • 8.3.2 BROTH MACRODILUTION
      • 8.3.2.1 Precision, simultaneous testing capability to drive market

9 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
  • 9.2 CLINICAL DIAGNOSTICS
    • 9.2.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
  • 9.3 DRUG DISCOVERY & DEVELOPMENT
    • 9.3.1 EMPHASIS ON R&D AND INNOVATION TO SUPPORT DEMAND GROWTH
  • 9.4 EPIDEMIOLOGY
    • 9.4.1 NEED FOR BETTER UNDERSTANDING AND DECISION MAKING TO PROPEL ADOPTION
  • 9.5 OTHER APPLICATIONS

10 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 HOSPITALS & DIAGNOSTIC CENTERS
    • 10.2.1 HOSPITALS & DIAGNOSTIC CENTERS TO HOLD LARGEST MARKET SHARE
  • 10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 10.3.1 EMPHASIS ON PRODUCT DEVELOPMENT TO DRIVE MARKET
  • 10.4 ACADEMIC & RESEARCH INSTITUTES
    • 10.4.1 RISING R&D ACTIVITY AND SUPPORT FOR RESEARCH TO DRIVE MARKET
  • 10.5 CLINICAL RESEARCH ORGANIZATIONS
    • 10.5.1 EXPANSION OF CLINICAL TRIALS WORLDWIDE TO PROPEL MARKET GROWTH

11 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
    • 11.2.2 US
      • 11.2.2.1 US to hold largest share of North American market
    • 11.2.3 CANADA
      • 11.2.3.1 Favorable government initiatives to drive market growth
  • 11.3 EUROPE
    • 11.3.1 EUROPE: MACROECONOMIC OUTLOOK
    • 11.3.2 GERMANY
      • 11.3.2.1 Government initiatives for AMR to drive market
    • 11.3.3 FRANCE
      • 11.3.3.1 Focus on enhancing AMR surveillance to propel market
    • 11.3.4 UK
      • 11.3.4.1 New action plans for AMR to propel adoption
    • 11.3.5 ITALY
      • 11.3.5.1 Rising instances of AMR and high use of antibiotics to propel demand for testing
    • 11.3.6 SPAIN
      • 11.3.6.1 Rising AMR in gram-negative bacilli to drive market
    • 11.3.7 REST OF EUROPE
  • 11.4 ASIA PACIFIC
    • 11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
    • 11.4.2 JAPAN
      • 11.4.2.1 Industry-government collaborations for infectious disease management to support market growth
    • 11.4.3 CHINA
      • 11.4.3.1 Rising emphasis on AMR management to drive market
    • 11.4.4 INDIA
      • 11.4.4.1 Expanding government and industry efforts in clinical diagnostics to propel market growth
    • 11.4.5 AUSTRALIA
      • 11.4.5.1 Establishment and implementation of antimicrobial treatment guidelines to favor market growth
    • 11.4.6 SOUTH KOREA
      • 11.4.6.1 Need for rapid AMR detection to drive demand for automated AST systems
    • 11.4.7 REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    • 11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
    • 11.5.2 BRAZIL
      • 11.5.2.1 Rising emphasis on implementing AMR detection to drive market
    • 11.5.3 MEXICO
      • 11.5.3.1 Economic growth to support expansion of AST systems
    • 11.5.4 REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    • 11.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
    • 11.6.2 GCC COUNTRIES
      • 11.6.2.1 Healthcare infrastructural development initiatives to support growth
    • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
  • 12.3 REVENUE ANALYSIS
  • 12.4 MARKET SHARE ANALYSIS, 2023
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 12.5.5.1 Company footprint
      • 12.5.5.2 Region footprint
      • 12.5.5.3 Product footprint
      • 12.5.5.4 Type footprint
      • 12.5.5.5 Method footprint
      • 12.5.5.6 Application footprint
      • 12.5.5.7 End-user footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 12.7 VALUATION & FINANCIAL METRICS
    • 12.7.1 FINANCIAL METRICS
    • 12.7.2 COMPANY VALUATION
  • 12.8 BRAND/PRODUCT COMPARISON
  • 12.9 COMPETITIVE SCENARIO
    • 12.9.1 PRODUCT LAUNCHES & APPROVALS
    • 12.9.2 DEALS

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
    • 13.1.1 BIOMERIEUX SA
      • 13.1.1.1 Business overview
      • 13.1.1.2 Products offered
      • 13.1.1.3 Recent developments
        • 13.1.1.3.1 Product launches & approvals
        • 13.1.1.3.2 Deals
      • 13.1.1.4 MnM view
        • 13.1.1.4.1 Right to win
        • 13.1.1.4.2 Strategic choices
        • 13.1.1.4.3 Weaknesses & competitive threats
    • 13.1.2 BECTON, DICKINSON AND COMPANY
      • 13.1.2.1 Business overview
      • 13.1.2.2 Products offered
      • 13.1.2.3 Recent developments
        • 13.1.2.3.1 Deals
        • 13.1.2.3.2 Other developments
      • 13.1.2.4 MnM view
        • 13.1.2.4.1 Right to win
        • 13.1.2.4.2 Strategic choices
        • 13.1.2.4.3 Weaknesses and competitive threats
    • 13.1.3 THERMO FISHER SCIENTIFIC INC.
      • 13.1.3.1 Business overview
      • 13.1.3.2 Products offered
      • 13.1.3.3 Recent developments
        • 13.1.3.3.1 Product launches & approvals
        • 13.1.3.3.2 Deals
      • 13.1.3.4 MnM view
        • 13.1.3.4.1 Right to win
        • 13.1.3.4.2 Strategic choices
        • 13.1.3.4.3 Weaknesses and competitive threats
    • 13.1.4 DANAHER CORPORATION
      • 13.1.4.1 Business overview
      • 13.1.4.2 Products offered
      • 13.1.4.3 Recent developments
        • 13.1.4.3.1 Product launches & approvals
        • 13.1.4.3.2 Deals
      • 13.1.4.4 MnM view
        • 13.1.4.4.1 Right to win
        • 13.1.4.4.2 Strategic choices
        • 13.1.4.4.3 Weaknesses and competitive threats
    • 13.1.5 BIO-RAD LABORATORIES, INC.
      • 13.1.5.1 Business overview
      • 13.1.5.2 Products offered
        • 13.1.5.2.1 Deals
      • 13.1.5.3 MnM view
        • 13.1.5.3.1 Right to win
        • 13.1.5.3.2 Strategic choices
        • 13.1.5.3.3 Weaknesses and competitive threats
    • 13.1.6 BRUKER
      • 13.1.6.1 Business overview
      • 13.1.6.2 Products offered
      • 13.1.6.3 Recent developments
        • 13.1.6.3.1 Product launches & approvals
        • 13.1.6.3.2 Deals
    • 13.1.7 ROCHE DIAGNOSTICS
      • 13.1.7.1 Business overview
      • 13.1.7.2 Products offered
      • 13.1.7.3 Recent developments
        • 13.1.7.3.1 Product launches & approvals
        • 13.1.7.3.2 Deals
    • 13.1.8 MERCK KGAA
      • 13.1.8.1 Business overview
      • 13.1.8.2 Products offered
      • 13.1.8.3 Recent developments
        • 13.1.8.3.1 Deals
    • 13.1.9 ACCELERATE DIAGNOSTICS, INC.
      • 13.1.9.1 Business overview
      • 13.1.9.2 Products offered
      • 13.1.9.3 Recent developments
        • 13.1.9.3.1 Product launches & approvals
        • 13.1.9.3.2 Deals
        • 13.1.9.3.3 Other developments
    • 13.1.10 HIMEDIA LABORATORIES
      • 13.1.10.1 Business overview
      • 13.1.10.2 Products offered
    • 13.1.11 LIOFILCHEM S.R.L.
      • 13.1.11.1 Business overview
      • 13.1.11.2 Products offered
    • 13.1.12 ALIFAX S.R.L.
      • 13.1.12.1 Business overview
      • 13.1.12.2 Products offered
    • 13.1.13 CREATIVE DIAGNOSTICS
      • 13.1.13.1 Business overview
      • 13.1.13.2 Products offered
    • 13.1.14 SYNBIOSIS
      • 13.1.14.1 Business overview
      • 13.1.14.2 Products offered
    • 13.1.15 BIOANALYSE
      • 13.1.15.1 Business overview
      • 13.1.15.2 Products offered
  • 13.2 OTHER KEY PLAYERS
    • 13.2.1 ZHUHAI DL BIOTECH CO., LTD.
    • 13.2.2 ELITECHGROUP
    • 13.2.3 MAST GROUP LTD.
    • 13.2.4 CONDALAB
    • 13.2.5 GENEFLUIDICS, INC.
    • 13.2.6 BIOTRON HEALTHCARE
    • 13.2.7 INVIVOGEN
    • 13.2.8 MP BIOMEDICALS
    • 13.2.9 QUANTAMATRIX INC.
    • 13.2.10 SYSMEX EUROPE SE
    • 13.2.11 COPAN DIAGNOSTICS INC.
    • 13.2.12 ERBA DIAGNOSTICS MANNHEIM GMBH

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
Show more
Product Code: MD 5931

List of Tables

  • TABLE 1 ANTIMICROBIAL SUSCEPTIBILITY TESTINGMARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 LIMITATIONS AND ASSOCIATED RISKS
  • TABLE 3 MITIGATION OF ANTIMICROBIAL RESISTANCE
  • TABLE 4 COMPARISON OF ANTIMICROBIAL SUSCEPTIBILITY TESTING AUTOMATED PRODUCT PRICING
  • TABLE 5 DISCREPANCIES BETWEEN FDA-APPROVED AST CRITERIA AND CDC-IDENTIFIED ANTIMICROBIAL RESISTANCE THREATS
  • TABLE 6 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: IMPACT OF PORTER'S FIVE FORCES
  • TABLE 8 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP FOUR END USERS (%)
  • TABLE 9 KEY BUYING CRITERIA, BY END USER
  • TABLE 10 LIST OF MAJOR PATENT INNOVATIONS AND PATENT REGISTRATIONS, 2022-2024
  • TABLE 11 IMPORT DATA FOR HS CODE 3822, BY COUNTRY, 2019-2023 (USD THOUSAND)
  • TABLE 12 EXPORT DATA FOR HS CODE 3822, BY COUNTRY, 2019-2023 (USD THOUSAND)
  • TABLE 13 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
  • TABLE 14 US FDA: MEDICAL DEVICE CLASSIFICATION
  • TABLE 15 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 16 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 17 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICALS AND MEDICAL DEVICES AGENCY
  • TABLE 18 CHINA: CLASSIFICATION OF MEDICAL DEVICES
  • TABLE 19 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 21 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 22 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 23 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 24 AVERAGE SELLING PRICE OF AST PRODUCTS, BY REGION, 2021-2023 (USD THOUSAND)
  • TABLE 25 AVERAGE SELLING PRICE OF TOP 3 APPLICATIONS, BY KEY PLAYER, 2023 (USD)
  • TABLE 26 US: MAJOR CPT CODES ASSOCIATED WITH AST, 2023
  • TABLE 27 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: CURRENT UNMET NEEDS
  • TABLE 28 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 29 ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 30 ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 31 CULTURE & GROWTH MEDIA MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 32 SUSCEPTIBILITY TESTING DISKS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 33 MIC STRIPS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 34 SUSCEPTIBILITY TESTING PLATES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 35 ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 36 ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 37 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 38 MOLECULAR DIAGNOSTICS SYSTEMS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 39 LAB DISPOSABLES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 40 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 41 ANTIBACTERIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 42 US: DEATHS FROM FUNGAL DISEASES, 2021
  • TABLE 43 ANTIFUNGAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 44 ANTIPARASITIC SUSCEPTIBILITY TESTING MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 45 ANTIVIRAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 46 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2022-2029 (USD MILLION)
  • TABLE 47 QUALITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 48 QUALITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 49 AVAILABLE AND EMERGING AUTOMATED AST TECHNOLOGIES
  • TABLE 50 AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 51 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR DISK DIFFUSION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 52 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR AGAR DILUTION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 53 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR GENOTYPIC METHOD, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 54 QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 55 QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 56 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR ETEST METHOD, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 57 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR BROTH MACRODILUTION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 58 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 59 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 60 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 61 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR EPIDEMIOLOGY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 62 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 63 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 64 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 65 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 66 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 67 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR CLINICAL RESEARCH ORGANIZATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 68 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 69 NORTH AMERICA: MACROINDICATORS
  • TABLE 70 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 71 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 72 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 73 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 74 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 75 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 76 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2022-2029 (USD MILLION)
  • TABLE 77 NORTH AMERICA: QUALITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 78 NORTH AMERICA: QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 79 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 80 US: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 81 US: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 82 US: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 83 CANADA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 84 CANADA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 85 CANADA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 86 EUROPE: MACROINDICATORS
  • TABLE 87 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 88 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 89 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 90 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 91 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 92 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 93 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2022-2029 (USD MILLION)
  • TABLE 94 EUROPE: QUALITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 95 EUROPE: QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 96 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 97 GERMANY: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 98 GERMANY: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 99 GERMANY: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 100 FRANCE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 101 FRANCE: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 102 FRANCE: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 103 UK: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 104 UK: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 105 UK: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 106 ITALY: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 107 ITALY: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 108 ITALY: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 109 SPAIN: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 110 SPAIN: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 111 SPAIN: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 112 REST OF EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 113 REST OF EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 114 REST OF EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: MACROINDICATORS
  • TABLE 116 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 118 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 120 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 121 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 122 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2022-2029 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: QUALITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 124 ASIA PACIFIC: QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 125 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 126 JAPAN: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 127 JAPAN: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 128 JAPAN: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 129 CHINA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 130 CHINA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 131 CHINA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 132 INDIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 133 INDIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 134 INDIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 135 AUSTRALIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 136 AUSTRALIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 137 AUSTRALIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 138 SOUTH KOREA: LIST OF CONFERENCES ON ANTIMICROBIAL ACTIVITY, 2024
  • TABLE 139 SOUTH KOREA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 140 SOUTH KOREA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 141 SOUTH KOREA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 142 REST OF ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 143 REST OF ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 144 REST OF ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 145 LATIN AMERICA: MACROINDICATORS
  • TABLE 146 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 147 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 148 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 149 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 150 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 151 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 152 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2022-2029 (USD MILLION)
  • TABLE 153 LATIN AMERICA: QUALITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 154 LATIN AMERICA: QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 155 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 156 BRAZIL: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 157 BRAZIL: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 158 BRAZIL: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 159 MEXICO: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 160 MEXICO: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 161 MEXICO: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 162 REST OF LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 163 REST OF LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 164 REST OF LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 165 MIDDLE EAST & AFRICA: MACROINDICATORS
  • TABLE 166 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 167 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 168 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 169 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 170 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 171 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 172 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2022-2029 (USD MILLION)
  • TABLE 173 MIDDLE EAST & AFRICA: QUALITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 174 MIDDLE EAST & AFRICA: QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 175 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 176 GCC COUNTRIES: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 177 GCC COUNTRIES: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 178 GCC COUNTRIES: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 179 REST OF MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 180 REST OF MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 181 REST OF MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 182 OVERVIEW OF STRATEGIES ADOPTED BY KEY MARKET PLAYERS
  • TABLE 183 ANTIMICROBIAL SUSCEPTIBILITY MARKET: DEGREE OF COMPETITION
  • TABLE 184 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: REGION FOOTPRINT
  • TABLE 185 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: PRODUCT FOOTPRINT
  • TABLE 186 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: TYPE FOOTPRINT
  • TABLE 187 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: METHOD FOOTPRINT
  • TABLE 188 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: APPLICATION FOOTPRINT
  • TABLE 189 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: END-USER FOOTPRINT
  • TABLE 190 ANTIMICROBIAL SUSCEPTIBILITY MARKET: FRANCE DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • TABLE 191 ANTIMICROBIAL SUSCEPTIBILITY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 192 ANTIMICROBIAL SUSCEPTIBILITY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021- SEPTEMBER 2024
  • TABLE 193 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: DEALS, JANUARY 2021- SEPTEMBER 2024
  • TABLE 194 BIOMERIEUX: COMPANY OVERVIEW
  • TABLE 195 BIOMERIEUX: PRODUCTS OFFERED
  • TABLE 196 BIOMERIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 197 BIOMERIEUX: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 198 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 199 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
  • TABLE 200 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 201 BECTON, DICKINSON AND COMPANY OTHER DEVELOPMENTS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 202 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW
  • TABLE 203 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED
  • TABLE 204 THERMO FISHER SCIENTIFIC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 205 THERMO FISHER SCIENTIFIC: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 206 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 207 DANAHER CORPORATION PRODUCTS OFFERED
  • TABLE 208 DANAHER CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 209 DANAHER CORPORATION: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 210 BIO-RAD LABORATORIES: COMPANY OVERVIEW
  • TABLE 211 BIO-RAD LABORATORIES: PRODUCTS OFFERED
  • TABLE 212 BIO-RAD LABORATORIES: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 213 BRUKER: COMPANY OVERVIEW
  • TABLE 214 BRUKER: PRODUCTS OFFERED
  • TABLE 215 BRUKER: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 216 BRUKER: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 217 ROCHE DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 218 ROCHE DIAGNOSTICS PRODUCTS OFFERED
  • TABLE 219 ROCHE DIAGNOSTICS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 220 ROCHE DIAGNOSTICS: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 221 MERCK: COMPANY OVERVIEW
  • TABLE 222 MERCK: PRODUCTS OFFERED
  • TABLE 223 MERCK: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 224 ACCELERATE DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 225 ACCELERATE DIAGNOSTICS: PRODUCTS OFFERED
  • TABLE 226 ACCELERATE DIAGNOSTICS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 227 ACCELERATE DIAGNOSTICS: DEALS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 228 ACCELERATE DIAGNOSTICS: OTHER DEVELOPMENTS, JANUARY 2021-SEPTEMBER 2024
  • TABLE 229 HIMEDIA LABORATORIES: COMPANY OVERVIEW
  • TABLE 230 HIMEDIA LABORATORIES: PRODUCTS OFFERED
  • TABLE 231 LIOFILCHEM: COMPANY OVERVIEW
  • TABLE 232 LIOFILCHEM: PRODUCTS OFFERED
  • TABLE 233 ALIFAX: COMPANY OVERVIEW
  • TABLE 234 ALIFAX: PRODUCTS OFFERED
  • TABLE 235 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 236 CREATIVE DIAGNOSTICS: PRODUCTS OFFERED
  • TABLE 237 SYNBIOSIS: COMPANY OVERVIEW
  • TABLE 238 SYNBIOSIS: PRODUCTS OFFERED
  • TABLE 239 BIOANALYSE: COMPANY OVERVIEW
  • TABLE 240 BIOANALYSE: PRODUCTS OFFERED

List of Figures

  • FIGURE 1 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SEGMENTATION
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: RESEARCH DESIGN
  • FIGURE 4 KEY DATA FROM SECONDARY SOURCES
  • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 7 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 8 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION)
  • FIGURE 9 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 10 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE ESTIMATION: END-USER APPROACH
  • FIGURE 11 TOP-DOWN APPROACH
  • FIGURE 12 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
  • FIGURE 13 DATA TRIANGULATION METHODOLOGY
  • FIGURE 14 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 17 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 18 GEOGRAPHICAL SNAPSHOT OF ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
  • FIGURE 19 INCREASING RESEARCH ACTIVITIES AND ADVANCEMENTS IN AUTOMATED & MOLECULAR DIAGNOSTIC INSTRUMENTS TO DRIVE MARKET
  • FIGURE 20 NORTH AMERICAN MARKET TO HOLD LARGEST MARKET SHARE
  • FIGURE 21 HOSPITALS & DIAGNOSTIC CENTERS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 22 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 23 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 24 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 25 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 26 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 27 ANTIMICROBIAL SUSCEPTIBILITY TESTING: PORTER'S FIVE FORCES
  • FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP FOUR END USERS
  • FIGURE 29 KEY BUYING CRITERIA, BY END USER
  • FIGURE 30 PATENT ANALYSIS FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET (JANUARY 2013-DECEMBER 2023)
  • FIGURE 31 REVENUE SHIFT AND NEW REVENUE POCKETS
  • FIGURE 32 INVESTMENT AND FUNDING SCENARIO, 2019-2023
  • FIGURE 33 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019-2023
  • FIGURE 34 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2018-2022 (USD MILLION)
  • FIGURE 35 AVERAGE SELLING PRICE OF AST PRODUCTS, BY REGION, 2021-2023 (USD)
  • FIGURE 36 AVERAGE SELLING PRICE FOR TOP 3 APPLICATIONS, BY KEY PLAYER
  • FIGURE 37 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SNAPSHOT
  • FIGURE 38 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SNAPSHOT
  • FIGURE 39 CHINA: INCIDENCE OF INFECTIOUS DISEASES, 2023
  • FIGURE 40 REVENUE ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY MARKET, 2019-2023 (USD MILLION)
  • FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY MARKET (2023)
  • FIGURE 42 ANTIMICROBIAL SUSCEPTIBILITY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 43 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: COMPANY FOOTPRINT
  • FIGURE 44 ANTIMICROBIAL SUSCEPTIBILITY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 45 EV/EBITDA OF KEY VENDORS
  • FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 47 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 48 BIOMERIEUX: COMPANY SNAPSHOT (2023)
  • FIGURE 49 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • FIGURE 50 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
  • FIGURE 51 DANAHER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 52 BIO-RAD LABORATORIES: COMPANY SNAPSHOT
  • FIGURE 53 BRUKER: COMPANY SNAPSHOT
  • FIGURE 54 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
  • FIGURE 55 MERCK: COMPANY SNAPSHOT
  • FIGURE 56 ACCELERATE DIAGNOSTICS: COMPANY SNAPSHOT
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!